Egen Atkinson focuses on biotechnology and pharmaceutical investments in Venrock’s New York office. Prior to joining Venrock, Egen worked at ForSight Vision4 (acquired by Roche), where he helped launch and manage a phase I clinical trial for Age-Related Macular Degeneration. He also consulted on gene therapy pipeline development for Spark Therapeutics (Nasdaq: ONCE) prior to IPO. Egen has designed and/or conducted several nationally-presented clinical research studies at the Scheie Eye Institute, Hospital for Special Surgery, and Retina Institute of Hawaii.
Egen earned his MD from the University of Pennsylvania School of Medicine, where he graduated Alpha Omega Alpha and received the Spencer Morris Prize, awarded to the top graduating student in the class. He earned his MBA in Healthcare Management from the Wharton School, where he received a Kaiser Fellowship. Egen received his AB in Economics from Harvard University, where he played 4 years of NCAA Division I water polo, served as co-captain, and received the Collegiate Water Polo Association Scholar-Athlete of the Year award.